gamma-Oryzanol
CAS 11042-64-1
gamma-Oryzanol (CAS 11042-64-1) is a pharmaceutical compound with 0 bioactivity targets and 49 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
gamma-Oryzanol is linked to DTXSID6021084 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is gamma-Oryzanol used for in pharmaceutical contexts?
gamma-Oryzanol (CAS 11042-64-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for gamma-Oryzanol?
gamma-Oryzanol has 49 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Anti-neutrophil cytoplasmic antibody positive vasculitis, Disseminated intravascular coagulation, Immune-mediated lung disease, 5-hydroxyindolacetic acid increased, Alpha tumour necrosis factor increased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is gamma-Oryzanol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Gamma-Oryzanol with EU status "permitted".
What clinical phase is gamma-Oryzanol in?
No phase 1-4 clinical development badge is rendered for gamma-Oryzanol because the matched compound identifier rows do not contain a max-phase value.